Sirolimus-Coated Balloon Matches Stents for Coronary Artery Disease in TRANSFORM II Trial

The TRANSFORM II trial results, published in The Lancet, indicate a sirolimus-coated balloon (SCB) strategy is non-inferior to drug-eluting stents for target lesion failure at 12 months in de novo coronary artery disease patients. With TLF rates of 2.1% for SCB versus 2.4% for stents, this suggests an effective implant-free option for percutaneous coronary intervention, potentially for complex patient populations.